Hooper W D, Kavanagh M C, Herkes G K, Eadie M J
Department of Medicine, University of Queensland, Brisbane, Australia.
Br J Clin Pharmacol. 1991 Feb;31(2):171-4. doi: 10.1111/j.1365-2125.1991.tb05507.x.
Twelve subjects received a single oral dose (300 mg) of gabapentin and serial blood and urine samples were collected for drug measurements. Oral phenobarbitone (30-90 mg/day) was then administered to steady-state, and the gabapentin single dose study was repeated on day 42. Gabapentin was administered from days 49 to 52 to achieved steady-state, and further blood and urine samples were collected for drug measurements. Trough plasma phenobarbitone concentrations were monitored at frequent intervals. No statistically significant differences were observed in gabapentin Cmax, tmax, AUC, t1/2 or urinary drug recovery following single doses of gabapentin alone or combined with phenobarbitone. Phenobarbitone did not alter the disposition of gabapentin at steady state. Mean trough steady-state phenobarbitone concentrations were not significantly affected by concomitant gabapentin administration.
12名受试者口服了单剂量（300毫克）的加巴喷丁，并采集了系列血液和尿液样本用于药物测定。随后给予口服苯巴比妥（30 - 90毫克/天）直至达到稳态，并在第42天重复加巴喷丁单剂量研究。在第49至52天给予加巴喷丁以达到稳态，并采集更多血液和尿液样本用于药物测定。频繁监测苯巴比妥的谷血浆浓度。单独给予加巴喷丁或加巴喷丁与苯巴比妥联合给药后，加巴喷丁的Cmax、tmax、AUC、t1/2或尿药回收率均未观察到统计学上的显著差异。苯巴比妥在稳态时不改变加巴喷丁的处置。加巴喷丁的同时给药对苯巴比妥的平均谷稳态浓度没有显著影响。
